{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:14:07Z","timestamp":1794014047661,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eNeurologicalSci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ensci.2023.100468","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T13:53:46Z","timestamp":1685022826000},"page":"100468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Hany A.","family":"Zaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mavia","family":"Najam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarij","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nood Dhafi R.","family":"Al-Marri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Abdelgadir M.","family":"Elgassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Fayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman E.","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ensci.2023.100468_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.608130","article-title":"Intensive Care and Treatment of Severe Guillain\u2013Barr\u00e9 Syndrome","volume":"12","author":"Shang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ensci.2023.100468_bb0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.it.2022.02.003","article-title":"Guillain-Barr\u00e9 syndrome: expanding the concept of molecular mimicry","volume":"43","author":"Laman","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ensci.2023.100468_bb0015","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","article-title":"Global, regional, and national burden of Guillain\u2013Barr\u00e9 syndrome and its underlying causes from 1990 to 2019","volume":"18","author":"Bragazzi","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ensci.2023.100468_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ensci.2023.100468_bb0025","article-title":"Chohan a: recurrence of a rare subtype of Guillain-Barr\u00e9 syndrome following a second dose of the shingles vaccine","volume":"14","author":"Chohan","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.ensci.2023.100468_bb0030","first-page":"2568","article-title":"Immunotherapy of Guillain-Barr\u00e9 syndrome","volume":"14","author":"Liu","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ensci.2023.100468_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002826-200601000-00011","article-title":"Current therapeutic options in severe Guillain-Barr\u00e9 syndrome","volume":"29","author":"Shahar","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ensci.2023.100468_bb0040","first-page":"8","article-title":"Complications of therapeutic plasma exchange in patients with neurological disorders","volume":"19","author":"Afzali","year":"2020","journal-title":"Curr. J. Neurol."},{"key":"10.1016\/j.ensci.2023.100468_bb0045","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00134-022-06793-z","article-title":"Plasma exchange in the intensive care unit: a narrative review","volume":"48","author":"Bauer","year":"2022","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ensci.2023.100468_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577042","article-title":"Intravenous immunoglobulin promotes the proliferation of CD4+CD25+ Foxp3+ regulatory T cells and the cytokines secretion in patients with Guillain-Barr\u00e9 syndrome in vitro","volume":"336","author":"Zhang","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ensci.2023.100468_bb0055","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"Schmitz PI: a randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 study group","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ensci.2023.100468_bb0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00002826-199510000-00001","article-title":"A comparison between IVIg and plasma exchange in Guillain-Barr\u00e9 syndrome: a review and decision analysis of the two treatment modalities","volume":"18","author":"Dawson","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ensci.2023.100468_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.746389","article-title":"Association between the rate of treatment response and short-term outcomes in childhood Guillain-Barr\u00e9 syndrome","volume":"12","author":"Jin","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ensci.2023.100468_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285615610471","article-title":"A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain-Barr\u00e9 syndrome in upper Egypt","volume":"9","author":"Saad","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ensci.2023.100468_bb0075","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.ensci.2023.100468_bb0080","doi-asserted-by":"crossref","DOI":"10.11604\/pamj.2014.18.35.2911","article-title":"Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barr\u00e9 syndrome","volume":"18","author":"Charra","year":"2014","journal-title":"Pan. Afr. Med. J."},{"key":"10.1016\/j.ensci.2023.100468_bb0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1097-4598(200101)24:1<54::AID-MUS6>3.0.CO;2-9","article-title":"Intravenous immunoglobulin therapy for Guillain-Barr\u00e9 syndrome with IgG anti-GM1 antibody","volume":"24","author":"Kuwabara","year":"2001","journal-title":"Muscle Nerve"},{"issue":"133\u20137","key":"10.1016\/j.ensci.2023.100468_bb0090","article-title":"Plasma exchange versus intravenous immunoglobulin in children with Guillain Barr\u00e9 syndrome","volume":"13","author":"Elahi","year":"2019","journal-title":"J. Dow Univ. Health Sci. (JDUHS)"},{"key":"10.1016\/j.ensci.2023.100468_bb0095","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jocn.2006.03.020","article-title":"Pharmacoeconomics of therapy for Guillain-Barr\u00e9 syndrome: plasma exchange and intravenous immunoglobulin","volume":"14","author":"Tsai","year":"2007","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.ensci.2023.100468_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3233\/NRE-201640","article-title":"Functional outcomes following inpatient rehabilitation of Guillain-Barr&eacute; syndrome patients: intravenous immunoglobulins versus plasma exchange","volume":"48","author":"Bondi","year":"2021","journal-title":"NeuroRehabilitation."},{"key":"10.1016\/j.ensci.2023.100468_bb0105","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/mus.26831","article-title":"Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome","volume":"61","author":"Beydoun","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ensci.2023.100468_bb0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/tme.12169","article-title":"Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome","volume":"25","author":"Ye","year":"2015","journal-title":"Transfus. Med."},{"issue":"33","key":"10.1016\/j.ensci.2023.100468_bb0115","first-page":"157","article-title":"Comparison of effectiveness and unit cost of intravenous immunoglobulin (IVIG) and plasma exchange (PE) in therapy for Guillain-Barr\u00e9 syndrome in Ratchaburi hospital","volume":"4-5","author":"Rodprasert","year":"2014","journal-title":"\u0e27\u0e32\u0e23\u0e2a\u0e32\u0e23\u0e41\u0e1e\u0e17\u0e22\u0e4c\u0e40\u0e02\u0e15"},{"key":"10.1016\/j.ensci.2023.100468_bb0120","series-title":"Outcome of various treatments in Guillain\u2013Barr\u00e9 Syndrome in Children","first-page":"3","author":"Anwer","year":"2020"},{"key":"10.1016\/j.ensci.2023.100468_bb0125","series-title":"Intravenous Immune Globulin Vs Plasma Exchange in Guillain Barre Syndrome a 5 Year Retrospective Study (1995\u20132000)","author":"Ashalatha","year":"2002"},{"key":"10.1016\/j.ensci.2023.100468_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3329\/jninb.v5i2.43015","article-title":"Comparison of ICU outcomes between intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated patients with GuillainBarr\u00e9 syndrome in a neuro-intensive care unit in a Govt. Hospital of Bangladesh: a observational cohort study","volume":"5","author":"Mallick","year":"2019","journal-title":"J. Nat. Instit. Neurosci. Bangladesh"},{"key":"10.1016\/j.ensci.2023.100468_bb0135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF02229327","article-title":"High dose intravenous immune globulins and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"16","author":"Ravasio","year":"1995","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/j.ensci.2023.100468_bb0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology."},{"key":"10.1016\/j.ensci.2023.100468_bb0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barr\u00e9 syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ensci.2023.100468_bb0150","first-page":"17","article-title":"A randomized trial comparing intravenous immune globlulin and plasma exchange in gullain \u2013 barre syndrome","volume":"16a","author":"Cecil","year":"2014"},{"key":"10.1016\/j.ensci.2023.100468_bb0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Plasma exchange\/Sandoglobulin Guillain-Barr\u00e9 syndrome trial group","volume":"349","year":"1997","journal-title":"Lancet."},{"key":"10.1016\/j.ensci.2023.100468_bb0160","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/(SICI)1097-4598(199810)21:10<1327::AID-MUS14>3.0.CO;2-Z","article-title":"Relapses in the Guillain-Barr\u00e9 syndrome after treatment with intravenous immune globulin or plasma exchange","volume":"21","author":"Romano","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ensci.2023.100468_bb0165","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ensci.2023.100468_bb0170","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archpedi.1994.02170110096019","article-title":"Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barr\u00e9 syndrome","volume":"148","author":"Vajsar","year":"1994","journal-title":"Arch. Pediatr. Adolesc. Med."}],"container-title":["eNeurologicalSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650223000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650223000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:19:02Z","timestamp":1762503542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405650223000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":34,"alternative-id":["S2405650223000266"],"URL":"https:\/\/doi.org\/10.1016\/j.ensci.2023.100468","relation":{},"ISSN":["2405-6502"],"issn-type":[{"value":"2405-6502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eNeurologicalSci","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ensci.2023.100468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100468"}}